A 52-year-old woman with a 10-year history of rheumatoid arthritis presents with nephrotic syndrome and renal biopsy shows AA amyloidosis. What is the drug of choice to prevent further amyloid deposition and slow renal disease progression?
A. Tafamidis
B. Bortezomib
C. Colchicine
D. Lenalidomide
Explanation
Management of Secondary (AA) Amyloidosis
Key Point
Colchicine is the first-line agent for secondary AA amyloidosis by suppressing serum amyloid A (SAA) production through inhibition of IL-1β and IL-6 in inflammatory cells.
Pathophysiology of AA Amyloidosis
AA amyloidosis develops in chronic inflammatory conditions (rheumatoid arthritis, chronic infections, inflammatory bowel disease). The acute-phase reactant serum amyloid A (SAA) is persistently elevated and misfolds to form amyloid deposits, particularly in kidneys, liver, and spleen.
Mechanism of Colchicine
1.
Inhibits microtubule polymerization in neutrophils and macrophages
2.
Reduces production of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α)
3.
Decreases serum amyloid A (SAA) levels
4.
Prevents further amyloid fibril deposition and halts disease progression
Treatment Strategy for AA Amyloidosis
Loading diagram...
Colchicine Dosing & Monitoring
Dose: 0.5–1 mg daily (adjust for renal function)
Monitoring: SAA levels, serum creatinine, 24-hour urine protein
Goal: Reduce SAA to <10 mg/L to halt amyloid deposition
Adverse effects: GI upset, diarrhea; contraindicated in severe renal/hepatic disease
High-YieldNEET PG
Colchicine + aggressive control of the underlying inflammatory disease (DMARDs, biologics) is the cornerstone of AA amyloidosis management. Early intervention can stabilize or reverse renal disease.
Clinical Pearl
In this patient, optimizing rheumatoid arthritis control (e.g., TNF inhibitors, methotrexate) is equally important as colchicine — the goal is to lower SAA production at the source.
